A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Interventional Cardiac Electrophysiology"
DOI: 10.1007/s10840-018-0318-2
Abstract: PurposeThe ultrarapid delayed rectifier current (IKur) carried by Kv1.5 channels, which are solely expressed in the atrium, is a potential target for safer treatment of paroxysmal atrial fibrillation (PAF). XEN-D0103 is a nanomolar ion channel… read more here.
Keywords: xen d0103; treatment; beat beat; placebo ... See more keywords